ECG with no clinically significant findings as assessed by the investigator . 6. No history of clinically significant autoimmune disease, HIV infection or other immunosuppressive disease. 7. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1. 8. Women of childbearing potential must have a negative serum pregnancy test and agree to remain sexually abstinent, have a partner who is sterile (i.e., vasectomy), or use two medically effective methods of contraception (e.g. oral contraception, barrier me thods, spermicide, intrauterine device (IUD)). Males with reproductive potential must be willing to use a condom and have their female sexual partners use another form of contraception such as an IUD, spermicidal foam/gel/film/cream/suppository, diaphragm with spermicide, oral contraceptive, injectable progesterone, sub -dermal implant or a tubal ligation if the female partner could become pregnant. This requirement should be followed from screening through 24 weeks after last dose of immunotherapy. 9. Able and willing to comply with all study procedures . 11 Date: 8 April, 2016 v 2.1 INO-3112 UPCC # 39313 / HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol Study Population: (continued): Exclusion Criteria 1. Pregnant or breast -feeding subjects.